TDC
DRNA

Thompson Davis & Co’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Thompson Davis & Co’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$3K Buy
+200
New +$2.91K 0.01% 646

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Thompson Davis & Co's DRNA Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2018: 200 shares worth $3K. The stake represents 0.01% of the portfolio and ranks #646 among its holdings.

95 funds tracked by Wall St. Rank hold DRNA as of Q3 2018.

  • Thompson Davis & Co held 200 shares of Dicerna Pharmaceuticals, Inc. worth $3K as of Q3 2018.
  • Dicerna Pharmaceuticals, Inc. was a new Thompson Davis & Co position in Q3 2018.
  • Dicerna Pharmaceuticals, Inc. made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #646 holding.
  • 95 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.